Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4-CD8-Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus

被引:125
|
作者
Kato, Hiroshi
Perl, Andras
机构
[1] SUNY Upstate Med Univ, Coll Med, Dept Med, Div Rheumatol, Syracuse, NY 13210 USA
[2] SUNY Upstate Med Univ, Coll Med, Dept Microbiol & Immunol, Div Rheumatol, Syracuse, NY 13210 USA
[3] SUNY Upstate Med Univ, Coll Med, Dept Biochem & Mol Biol, Div Rheumatol, Syracuse, NY 13210 USA
基金
美国国家卫生研究院;
关键词
ROR-GAMMA-T; MAMMALIAN TARGET; DISEASE-ACTIVITY; DECREASED PRODUCTION; INTERFERON-GAMMA; HELPER-CELLS; MTOR KINASE; TGF-BETA; IN-VIVO; DIFFERENTIATION;
D O I
10.4049/jimmunol.1301859
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mechanistic target of rapamycin (mTOR) is activated in CD4-CD8-double-negative (DN) T cells and its blockade is therapeutic in systemic lupus erythematosus (SLE) patients. Murine studies showed the involvement of mTOR complex 1 (mTORC1) and 2 (mTORC2) in the differentiation of Th1/Th17 cells and Th2 cells, respectively. In this study, we investigated the roles of mTORC1 and mTORC2 in T cell lineage development in SLE and matched healthy control (HC) subjects. mTORC1 activity was increased, whereas mTORC2 was reduced, as assessed by phosphorylation of their substrates phosphorylated S6 kinase 1 or phosphorylated S6 ribosomal protein and phosphorylated Akt, respectively. Rapamycin inhibited mTORC1 and enhanced mTORC2. IL-4 expression was increased in freshly isolated CD8(+) lupus T cells (SLE: 8.09 +/- 1.93%, HC: 3.61 +/- 0.49%; p = 0.01). DN T cells had greater IL-4 expression than CD4(+) or CD8(+) T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 +/- 1.48%, rapamycin: 5.03 +/- 0.66%; p < 0.001). GATA-3 expression was increased in CD8(+) lupus T cells (p < 0.01) and was insensitive to rapamycin treatment. IFN-gamma expression was reduced in all lupus T cell subsets (p = 1.0 x 10(-5)) and also resisted rapamycin. IL-17 expression was increased in CD4(+) lupus T cells (SLE: 3.62 +/- 0.66%, HC: 2.29 +/- 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 +/- 0.79%, rapamycin: 2.22 +/- 0.60%; p < 0.001). Frequency of regulatory T cells (Tregs) was reduced in SLE (SLE: 1.83 +/- 0.25%, HC: 2.97 +/- 0.27%; p = 0.0012). Rapamycin inhibited mTORC1 in Tregs and promoted their expansion. Neutralization of IL-17, but not IL-4, also expanded Tregs in SLE and HC subjects. These results indicate that mTORC1 expands IL-4(+) DN T and Th17 cells, and contracts Tregs in SLE. The Journal of Immunology, 2014, 192: 4134-4144.
引用
收藏
页码:4134 / 4144
页数:11
相关论文
共 50 条
  • [41] Increased circulating CD4+CXCR5+FoxP3+ follicular regulatory T cells correlated with severity of systemic lupus erythematosus patients
    Liu, Chen
    Wang, Dongwei
    Song, Ying
    Lu, Songsong
    Zhao, Jingzhong
    Wang, Hui
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 56 : 261 - 268
  • [42] Increased HIF-1α expression in T cells and associated with enhanced Th17 pathway in systemic lupus erythematosus
    Liao, Hsiu-Jung
    Chu, Ching-Liang
    Wang, Szu-Chieh
    Lee, Hua-Yi
    Wu, Chien-Sheng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (12) : 2446 - 2456
  • [43] In vitro generated Th17 cells support the expansion and phenotypic stability of CD4+Foxp3+ regulatory T cells in vivo
    Zhou, Qiong
    Hu, Ya
    Howard, O. M. Zack
    Oppenheim, Joost J.
    Chen, Xin
    CYTOKINE, 2014, 65 (01) : 56 - 64
  • [44] CIRCULATING CD4+T CELLS LEVELS IN ACTIVE AND NON ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    Cairoli, Ernesto
    Cayota, Alfonso
    Jose Iriarte, Maria
    Irureta, Sebastian
    Rocha, Alex
    ACTA REUMATOLOGICA PORTUGUESA, 2009, 34 (03): : 559 - 560
  • [45] ASM is a therapeutic target in dermatomyositis by regulating the differentiation of naive CD4+T cells into Th17 and Treg subsets
    Chen, Yuehong
    Liu, Huan
    Luo, Zhongling
    Zhang, Jiaqian
    Dong, Min
    Yin, Geng
    Xie, Qibing
    SKELETAL MUSCLE, 2024, 14 (01):
  • [46] Identifying key genes in CD4+ T cells of systemic lupus erythematosus by integrated bioinformatics analysis
    Li, Zutong
    Wang, Zhilong
    Sun, Tian
    Liu, Shanshan
    Ding, Shuai
    Sun, Lingyun
    FRONTIERS IN GENETICS, 2022, 13
  • [47] LPS-Treated Podocytes Polarize Naive CD4+ T Cells into Th17 and Treg Cells
    Yuan, Da-Hai
    Jia, Yang
    Hassan, Omar Mohamud
    Xu, Li-Yun
    Wu, Xiao-Chuan
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [48] Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic
    Majchrzak, Kinga
    Nelson, Michelle H.
    Bailey, Stefanie R.
    Bowers, Jacob S.
    Yu, Xue-Zhong
    Rubinstein, Mark P.
    Himes, Richard A.
    Paulos, Chrystal M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (03) : 247 - 259
  • [49] IL-27 mediates immune response of pneumococcal vaccine SPY1 through Th17 and memory CD4+T cells
    Zhang, Yanyu
    Gao, Song
    Yao, Shifei
    Weng, Danlin
    Wang, Yan
    Huang, Qi
    Zhang, Xuemei
    Wang, Hong
    Xu, Wenchun
    ISCIENCE, 2023, 26 (08)
  • [50] Expansion of CD4+CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin
    Asanuma, Shinsuke
    Tanaka, Junji
    Sugita, Junichi
    Kosugi, Mizuha
    Shiratori, Souichi
    Wakasa, Kentarou
    Shono, Yusuke
    Shigematsu, Akio
    Kondo, Takeshi
    Kobayashi, Takahiko
    Asaka, Masahiro
    Imamura, Masahiro
    ANNALS OF HEMATOLOGY, 2011, 90 (06) : 617 - 624